Methods related to bronchial premalignant lesion severity and progression

1. A method of treating bronchial premalignant lesions, the method comprising:

administering:

i. a bronchoscopy-based procedure to survey the central airway and a chest CT scan; and

ii. at least one anti-proliferative drug;

to a subject presently lung cancer-free, but having bronchial premalignant lesions, and determined to have:

an increased level of expression of at least one module 5 gene in a sample obtained from the subject comprising morphologically-normal cells as compared to a non-proliferative lesion reference level, wherein the at least one module 5 gene is selected from the group consisting of:

RACGAP1 and TPX2;

a decreased level of expression of at least one module 6 gene in a sample obtained from the subject comprising morphologically-normal cells as compared to a non-proliferative lesion reference level, wherein the at least one module 6 gene is selected from the group consisting of:

NEK11 and IFT88

wherein the sample is a bronchial brushing obtained from the right or left mainstem bronchus, an endobronchial biopsy, endobronchial brushing sample, large airway biopsy, large airway brushing sample, nasal epithelial cells or sputum and wherein the sample is obtained from the subject while the subject is presently lung cancer-free, but having bronchial premalignant lesions.

2. The method of claim 1 , wherein the subject is further determined to have an increased level of expression of at least one module 7 or module 4 gene as compared to a non-proliferative lesion reference level;

wherein the at least one module 7 gene is selected from the group consisting of:

RPS20; EIF4B; RPL18; RPL31; RPS5; STARD7; RPL6; RPLP0; IGBP1; EIF3L; RPL3;

EIF3D; CCNB11P1; EIF3E; EEF1D; RPS16; FBL; RPS19; GLTSCR2; RPL18A;

DDX50; RPL28; RPL19; SMARCD2; RPL34; RPS13; C12orf57; RPS12; RPL24;

EEF1B2; RPS15; RPL22; DPH5; RPS25; CCNI; RPL21; RPL5; RPS10; RPL23;

SNRPD2; UROD; SERGEF; ECSIT; RPL36; MRPL34; COX4I1; RPL27; TPT1;

RPS15A; ATP5G2; RNASEH2B; CCDC115; RPL35; POLR1E; RPS6; RPLP1;

RPL7P9; RPS24; RPL14P1; GCSH; RPS2; RPS11; RPL13A; RPL11; RPS8; RPS27A;

RPL32; SLC25A26; RPS3A; RPL37; BTF3; RPL10; RPL7; EBAG9; EIF3H; RPL7A;

RPS3; FAU; TMEM18; RPL30; EEF1A1; ZNF689; RPL8; RPL26; RPL29; PMVK;

RPL9; RPS14; RPL27A; MRPL16; RPL13; RPSA; SLC25A6; CNBP; RPS9; RPS21;

RPS7; RPL38; TOMM20; RPL4; MRPL11; RPL15; FAM211A-AS1; EIF3F; ZFAS1;

RPLP2; RPS27; RPS17L; RPL35A; RPS7P1; RPS17; RPS23; COMMD6; RPL14;

RPS2P46; EEF1A1P5; NACA; TOMM7; RPL37A; RPL12; RPS4X; RPL23A; ZNF511;

RPL10A; RPL39; C6orf48; GNB2L1; RPSAP58; RPL15P3; RPL18AP3; RPLP0P6;

RPS29; RPL21P75; SMIM7; LYRM4; RPS3AP26; RPL7P1; PHB2; RPL21P28;

UBA52; RPL41P1; RPL41; RPL4P4; RPS23P8; RPS18; EEF1B2P3; RPL3P4;

EEF1A1P6; RPS28; GASS, RPS3AP6; RPL24P2; RPL6P27; RPL13AP5; RPS2P5;

RPL36A; RPL7AP6; SNHG6; EEF1G; RPL17; and SNHG8; and

wherein the at least one module 4 gene is selected from the group consisting of:

MRPS24; NDUFB4; NDUFB2; PSMD8; NDUFB7; TOMM22; TCEB2; CHCHD2;

PSMD9; MRPL51; COX6A1; COX7A2; ATP5F1; NDUFB3; PDZD11; NDUFA1;

MRPS7; ROMO1; COX6B1; TIMM17B; UQCR11; EMC6; COX7B; BLOC1S1;

COXSB; PSMB7; NDUFB10; ANAPC11; TXNL4A; SNRPG; NDUFS6; TIMM8B;

NDUFC2; DBI; C14orf2; THOC7; UQCRQ; COX6C; NDUFB6; STOML2; NDUFB8;

ATP5I; UQCRFS1; MRPL36; MYEOV2; CHCHD1; MINOS1; USMG5; COX8A;

POLR2L; TMEM11; COX5A; MRPL54; UQCR10; NDUFA12; DRG1; NDUFA13;

SUMO2; NDUFA4; GPN1; C11orf83; NDUFS3; ATP5J2, and MRPL12.

3. The method of claim 2 , wherein the at least one module 7 or module 4 gene is selected from the group consisting of:

COX6A1; COX7A2; RPL26; and RPL23.

4. The method of claim 1 , wherein the anti-proliferative drug is administered as an inhaled formulation, topical formulation, during a bronchoscopy-based procedure, or systemically.

5. The method of claim 1 , wherein the subject is further determined to have a decreased level of expression of at least one module 9 gene as compared to a non-proliferative lesion reference level and/or an increased level of expression of at least one module 10 gene as compared to a non-proliferative lesion reference level;

wherein the at least one module 9 gene is selected from the group consisting of:

LAP3; NUB1; CD74; BTN3A1; EIF2AK2; PARP12; SP100; IFI35; LAG3; PSME1;

APOL4; APOL1; PSME2; TRIM14; DDX58; OAS3; OAS2; BTN3A3; BTN2A1;

XRN1; IFIH1; STAT1; GBP1; IFIT3; TNFSF10; OPTN; NMI; ZNFX1; RNF114;

BTN2A2; IRF1; IFI6; APOL3; APOL2; BST2; KLHDC7B; HELZ2; IDO1; TRIM21;

TRIM22; EPSTI1; CMPK2; TRAFD1; TOR1B; DDX60; IFI44L; IFI44; PARP9;

HERC6; CXCL9; WARS; PML; NLRC5; IFIT5; UBE2L6; MX1; USF1; ADAR; LY6E;

GBP4; DTX3L; IL15; IFI27; C2; B2M; BATF2; TAP1; LGALS9; CXCL10; PARP14;

RNF213; SAMD9L; HLA-DQB1; CIITA; SOCS1; SP140L; TRIM69; BTN3A2; ISG15;

RUFY4; PLSCR1; HLA-DRB1; HLA-DQA1; ACSL5; C5orf56; HLA-DOA; HLA-DMA;

TAPSAR1; PSMB8; HLA-DRA; HLA-C; HLA-E; HLA-F; PSMB10; EXOC3L4;

HCP5; HLA-A; UBD; IRF9; APOL6; HLA-DPB1; PSME2P2; GBP1P1; HLA-DPA1;

TAPBP; HLA-DQB2; HLA-B; OR2I1P; PSMB9; and HLA-DMB; and

wherein the at least one module 10 gene is selected from the group consisting of:

CACNB3 and MAPK10.

6. The method of claim 5 , wherein the subject determined to have a decreased level of expression of at least one module 9 gene and/or an increased level of expression of at least one module 10 gene is administered at least one of:

i. both a bronchoscopy-based procedure to survey the central airway wherein the lesions are biopsied to remove abnormal tissue and a chest CT scan;

ii. at least every 6 months, one of a bronchoscopy-based procedure to survey the central airway wherein the lesions are biopsied to remove abnormal tissue and a chest CT scan; and/or

iii. at least one immune stimulating drug.

7. The method of claim 1 , wherein the sample comprises morphologically normal tissues, or consists of morphologically-normal tissues or cells.

8. The method of claim 1 , wherein the level of expression is the level of expression in a sample further comprising bronchial premalignant lesion cells.

9. The method of claim 1 , wherein the subject is a smoker or former smoker.

10. The method of claim 1 , wherein the bronchoscopy-based procedure and the chest CT scan are administered at a frequency of at least every 6 months.

11. The method of claim 10 , wherein administering the bronchoscopy-based procedure and the chest CT scan to the subject at a frequency of at least every 6 months comprises instructing the subject to repeat the administration of the bronchoscopy-based procedure and the chest CT scan within 6 months.

12. The method of claim 1 , wherein the at least one module 5 gene comprises at least RACGAP1 and TPX2; and the at least one module 6 gene comprises at least NEK11 and IFT88.

13. The method of claim 1 , wherein the subject is one who does not presently have and has not previously had lung cancer.

14. The method of claim 1 , wherein the subject further has:

an increased level of expression, in a sample obtained from the subject comprising morphologically-normal cells as compared to a non-proliferative lesion reference level, of at least one module 5 gene selected from:

Clorf112; POLDIP2; DBF4; E2F2; NCAPD2; ANLN; DEPDC1; UHRF1;

SPDL1; TSPAN17; RFC2; RAD51; NOP58; ASPM; PRR11; HMMR; GTSE1;

WDR62; UBE2T; NDC80; ORC1; RAD54L; PIGS; AURKA; BIRCS; KIF4A;

ORC6; CDC45; CDC6; CDC7; MCMS; CDKN3; LGMN; GINS1; MYBL2;

E2F1; SUV39H1; CENPI; GABPB1; MCM4; RNASEH2A; ASF1B; ILVBL;

EZH2; UBE2S; NCAPG; FOXM1; RAD51AP1; RFCS; TIMELESS; MCM3;

BYSL; TTK; KIF20A; LMNB1; SMC4; LRRC42; HDAC1; TTF2; CDC20;

STMN1; CENPF; KIF14; HELLS; MTHFD1L; MASTL; CCDC77; TMPO;

NCAPH; KIF18A; CCDC18; HNRNPA2B1; ZWINT; CENPK; TUBA1B;

HJURP; CKS2; CSE1L; SOX4; C17orf53; HNRNPR; DLGAPS; PKMYT1;

A4GALT; KNSTRN; FAM64A; PVRL2; GINS2; ABCB7; TOP2A; MRPL35;

PCNA; CCNB1; CDCA8; TROAP; ESPL1; URB2; STX6; CKAP2; BORA;

BRIP1; CTSV; CPEB2; NUSAP1; KIF23; CASCS; CENPO; KIF11; CEP55;

WDR12; CENPE; BRCA2; DENR; DIAPH3; FANCI; PLK4; KIF2C; NUF2;

DTL; INTS7; ILF2; CHAC2; FANCD2; CCNA2; SKP2; G3BP1; MTFR2;

CDCAS; NCAPG2; NONO; RBMX; GINS4; MKI67; CHEK1; TEX30; CENPH;

SKA1; EME1; BUB1B; CCNB2; CHAF1B; SPC24; C16orf59; CCNF;

KIAA1524; KIF15; RPL39L; SLBP; CDC25A; MAD2L1; PTTG1; MELK;

SKA3; CENPN; KIAA0101; PLK1; CDT1; TK1; PBK; DTYMK; RFWD3;

FEN1; USP39; CKAP2L; BUB1; CDK1; SHCBP1; ESCO2; RRM2; CKS1B;

ZWILCH; UBE2C; CKAPS; CCNE2; TYMS; B3GNT8; AURKB; RCC2;

FARSA; MAF1; KPNA2; SKA2; TRAIP; LIN9; IQGAP3; CDCA2; PARPBP;

KIF18B; ERCC6L; PTMA; FANCA; H2AFX; FAM72B; FAM111B; XRCC6;

FAM72A; XRCC2; HYLS1; ARHGAP11A; PRC1; CENPW; LSM2; TRIM59;

FAM72D; DHFR; KIFC1; and PGAM5; or

the subject further has a decreased level of expression, in a sample obtained from the subject comprising morphologically-normal cells as compared to a non-proliferative lesion reference level, of at least one module 6 gene selected from:

STPG1; KLHL13; SLC7A2; ZMYND10; ARX; DHX33; WDR54; ARHGAP44;

CDKL3; PROM1; DNAH9; GAS7; RHBDF1; TEAD3; JARID2; FUZ;

LRRC23; MKS1; TTC19; PPP5C; IL2ORA; GLT8D1; PLEKHB1; NRXN3;

CCDC28A; HSF2; TOMM34; CD44; EFCAB1; USP2; NSUN2; DNAH5;

SPATA7; TRIT1; CC2D2A; SNX29; R3HDM1; SRD5A2; NEDD4L; PPP1R3F;

ARHGEF5; POLQ; LY75; SDCCAG8; HHAT; GALC; GYG2; DCBLD2;

LAMC2; SPA17; SNCAIP; ANKS1A; DGKA; TBC1D22B; FOXJ2; DIP2B;

ZMYND12; NGEF; EML1; EVI5; TP53BP1; ATP11A; IFT80; PPP2R5B;

MNT; AP3M2; ST6GALNAC2; C16orf80; TRIP13; RPS6KA6; RHOBTB1;

XRCC1; CLCN4; SLC24A1; ARHGEF1OL; SRI; GRAMD4; TMEM131;

KIFAP3; SPAG6; POLD3; FKBP6; TULP3; ZCWPW1; TP73; OSBPL6;

CDC14A; RFX3; PIH1D3; HSP90AA1; HSPB11; ULK2; MAPRE3; CD59;

WDR47; NFX1; IPO11; MTMR2; ATXN7L3; SF3B2; TFAP2C; RFX2; GP6;

REM1; KIF9; NSFL1C; PLK1S1; DYNLL1; SLC8B1; DZANK1; C20orf26;

TASP1; NUDC; CERS4; NAT14; IL5RA; TEKT2; PSMD5; NUP188; ITPR3;

IFT74; SEC14L3; ANKRD54; CENPM; CBY1; RTDR1; RAB36; TTLL1;

MCAT; MYH9; DESI1; CERK; KHNYN; PRMT5; CDKL1; SAMD15;

AHSA1; SIX4; RPS6KA5; IFT52; SPEF1; EPPIN; MOSPD1; ASB9; PCYT1B;

KLF8; FGF14; CDADC1; MRPS31; SLC25A15; KATNAL1; GDPD3; MMP15;

CCDC113; SLC38A7; HSDL1; NAGPA; USP10; METRN; CLUAP1;

RPGRIP1L; CCP110; IQCH; CORO2B; ACSBG1; ZNF106; CEP152; RP1;

NIPAL2; ZC2HC1A; CHRAC1; NCALD; SQLE; TUSC3; POLR2I; ZFR2;

CAPS; TTC26; RNF32; IQCE; HIBADH; TAX1BP1; FAM188B; RPA3; NRF1;

CEP41; FSD1L; AK1; RGP1; MPDZ; GLIS3; HPS1; LZTS2; SH3PXD2A;

PBLD; TRIM37; DHX40; GALK1; B9D1; PEX12; HNF1B; PPP1R9B;

PRKAR1A; EFNB3; IFT20; SLAIN2; WFS1; TBC1D19; WHSC1; SNX25;

LRP2BP; Cllorf63; SNX15; KIAA1377; PPFIBP1; ELK3; PRMT8; AKAP3;

KCNA1; LTBR; OGFOD2; STX2; MDM1; UHRF1BP1L; ENO2; ST8SIA1;

RSPH4A; MAK; MCM9; FAM184A; TPD52L1; SASH1; RBM24; CAP2;

PACRG; C6orf118; MDFI; FAM120B; DNPH1; ENPP5; NME5; IK; MSH3;

RAD1; C5orf15; WWC1; CLDN16; ARL6; IFT57; HHLA2; IQCG; KIAA1257;

PLCH1; NEK4; STEAP3; STAM2; NRBP1; DNAH6; PECR; GGCX; PPP1R7;

TAF1B; ORC4; THADA; C2orf42; GRIN3B; ALMS1; BCL9; TRIM62;

DNAJC6; PHTF1; OSCP1; TBCE; RIMS3; CCDC181; RCAN3; IFT46;

CASC1; FILIP1; HMGN3; UBE3D; ARMC2; WDR35; DNAH7; C2orf40;

FAM206A; WDR34; CNTRL; TRIM32; FBXW2; CCDC176; ACYP1; IFT43;

DNAL1; TTLL5; DLST; PPP4R4; ZC2HC1C; FKBP1B; CCDC147; C10orf95;

LRP11; CCDC170; MYCT1; CYSTM1; ENOX1; PROSER1; HSPH1; AKAP1;

ZSCAN18; TRMT1L; CRY2; FAM35A; BBS9; IFT81; TTC21B; B9D2;

DAW1; ENKD1; C20orf85; TCP11; COL21A1; BBS2; PTGER2; TEKT3;

TTF1; C20orf195; TRIP10; PANK2; MGME1; ID1; ERGIC3; HECTD3;

FRMD8; PRDX5; PCNXL4; KTN1; SIX1; WDR60; LRRC61; TUBA4A;

TNFRSF19; AKAP9; STYXL1; C22orf23; RIBC2; CDHR3; RABL5;

KLHDC10; TTBK2; C15orf57; CALML4; THAP10; BBOX1; LRRC6; EGLN3;

FOXJ1; CDC16; RSPH3; STK33; CACNG6; SSBP4; UBAC1; TUBGCP2;

ARHGEF16; ATPIF1; PRRG1; KIF3A; PSMC3IP; NPHP4; MAP1B; PDHA1;

ZSCAN5A; RHPN2; ABHD12B; ZSWIM4; FBXW9; ZNF20; SPATA6;

GAS2L2; CNGA4; IQCA1; VPS13B; RGS22; BTBD3; POLR3F; DPH2;

PIK3C2B; SLC41A1; SPG20; STOML3; MORC4; EPHB2; PDE6B; SEC14L4;

ACTR3B; LRRIQ1; TMEM254; LRRCC1; UNC79; MEIS2; PTGFRN; ISCAl;

CCDC146; HILPDA; KIAA1009; LCA5; PRPH; KCNH3; CD164; LACE1;

PKIB; REPS1; ARMC9; TSGA10; TGFBRAP1; APPL2; TTC5; NMT1;

MYCBPAP; VEZF1; SAP130; ODF2; WDR38; SLC22A23; BPHL; FAM8A1;

C6orf52; TTC29; ANKRD42; NEK1; C11orf70; BTG4; PAQR5; LRRC49;

GIPC2; IFT172; DYNC2L11; SMEK2; ARL3; MDH1B; CIR1; ABI2; MNS1;

HCN4; FAM13A; RASGEF1B; CDKL2; SHROOM3; MTTP; CCDC65;

CERS5; MORN3; C14orf37; SLC38A6; EFCAB11; PTGR2; AK7; SLC27A2;

DNAJA4; BBS4; CCDC33; WDR93; FURIN; SH3GL3; GLYR1; NUDT7;

GALNS; GASB; GFOD2; LRRC46; BCAS3; WRAP53; TP53; WDR45B;

FBX015; FHAD1; PEX14; IL22RA1; STRIP1; NME7; UCK2; UFC1; USP21;

DYRK3; SMYD2; ADAM15; AQP10; Clorf131; SCCPDH; CNIH3; CALM2;

WDPCP; NPHP1; AMMECR1L; SPAG16; ANKMY1; CCDC39; TRMT10A;

NAF1; ROPN1L; FAM50B;FARS2; DCDC2; RNF44; TCTE1; CYP39A1;

TPBG; IRAK1BP1; ARHGAP18; GBAS; PSPH; AGBL3; TMEM27; ZNF157;

DIAPH2; PRPS1; CXorf57; MCPH1; CETN2; CHMP7; C9orf72; IDNK;

ASTN2; WDR31; CAMK2G; LRRC27; CNNM2; ZNF214; Cllorf49; CCDC81;

TTC12; C11orf52; GLB1L2; MTA2; MPZL2; PLCB3; CTF1; TMEM218;

N6AMT2; SPATA4; FSIP1; DIXDC1; PIH1D2; C2orf50; ENKUR; DCP1B;

AKAP6; MIPOL1; NUBPL; VIPAS39; TEX9; INPP1; CCDC122; NBAS;

CCDC74B; RPP38; TRIM36; SPEF2; CAPSL; WDR78; IFLTD1; CLGN;

CETN3; CCDC148; FAM81B; ADPRHL1; FBXL2; UBP1; LURAP1L; CFDP1;

FAM92B; FBXO36; ZNF599; DDAH1; ANKFN1; FAM105B; FAM134B;

CEP112; ENAH; CCDC173; SORBS2; SLFN13; RAB6B; ACSS1; RSPH10B;

AK9; AZIN1; AGPAT5; LRGUK; KDM8; ALS2CR12; SPAG17; FMN2;

GRIP1; ELMSAN1; GNA14; FAM161B; DRAM2; C8orf37; C15orf26;

WHAMM; TIAM1; RPGR; SH3RF2; GALK2; MMP14; Clorf158; HYDIN;

ZNF19; FAM81A; DSCR3; LCA5L; C9orf43; WDR19; DRC1; RAB28;

WDR66; LRRC43; AAED1; FAIM; SLC13A3; RIBC1; C2orf62; KCNB1;

DNAH3; AGPAT6; B4GALT3; C21orf59; C2orf81; CHCHD6; TPPP3;

ZDHHC1; IQCC; KALRN; TMPRSS3; RSPH1; C9orf116; PCSK7; RUSC1;

UBQLN4; TONSL; ORAI2; LRWD1; FBXL13; DUSP14; LRRC56; FDXR;

ALOX15; HS3ST6; SHANK2; PPP1R32; RPS6KA4; UBXN10; Clorf87;

OMA1; DNAJB4; LRRIQ3; WDR63; KLHDC9; FLVCR1; SPATA17;

DUSP19; CCDC104; CCDC138; CCDC74A; TEKT4; SPATA18; INHBB;

BBS5; RPRD2; PACRGL; DHX57; FZD5; Clorf189; FAM175A; HIPK1;

NEK10; AZI2; GLB1L; EFHB; ICA1L; KIAA1407; CDS1; GMPS; ABHD6;

LZTFL1; MEAF6; DNALI1; EXO5; PRSS12; MAPS; CEP44; ZNF474;

PRIMPOL; GDF9; GJB7; TXLNB; DCBLD1; KIAA0895; KIF6; SYTL3;

IQUB; C7orf57; MED30; HEATR2; TP531NP1; TMEM67; FAM219A;

C9orf24; ABCA1; C8orf34; KDM1B; C9orf64; SVEP1; CXorf22; KIAA1958;

STRBP; GAPVD1; ARMC3; LRRC18; DNAAF2; TTC8; AK8; C9orf9;

ZMYND19; STOX1; PPP1R36; CKB; DPCD; LARP6; C16orf71; FAM227B;

STXBP4; C10orf32; SMPD1; APBB1; C11orf65; C11orf74; TUB; XRRA1;

C16orf46; ZNF3; IQCD; RRAD; WDR16; CCNDBP1; MS4A8; MAP1A;

DUSP18; TTC16; COQ4; CCDC103; ENDOG; COQ7; KATNAL2; SPATA33;

RHEBL1; TUBA1A; DNAAF3; HSD11B1L; CYB5D2; TEKT1; TMEM68;

ZNF598; C2CD3; ULK4; MOBP; DEGS2; BMP1; SLC20A2; DYNLRB2;

VWA3B; LDLRAD4; PKIG; FAM178B; CXXC4; TCTN2; TNIP2; PPIC;

ZBBX; ARMC4; NSMCE1; RAB3B; ARL13B; MUC15; TPST1; TOR1AIP2;

FABP6; FAM161A; C14orf142; SPATA24; SLC23A1; HSD17B13; KIAA0232;

DCDC1; PRKCE; MORN4; RBKS; NAT1; LPAR3; MAP6; ZNF584; DNAI2;

LRRC34; CTPS1; KNDC1; AQP4; LRRC48; SNTB1; COPRS; CCDC11;

RSPH9; KLHL6; ZFAND4; ADH6; CCDC96; ABCD2; IQCB1; APOBEC4;

PIFO; CEP19; FAM174A; GSTA3; CHRNA9; C12orf76; BBS1; ZNF497;

IQCK; SH3PXD2B; WDR49; THAP6; BTC; CATSPERD; APITD1; EIF1AD;

TEX26; GPR156; RUVBL1; UNC119B; TMPRSS7; BNIP3; SMIM19; PRR18;

EID2B; PLA2G16; CNTD1; MAP3K19; CCDC121; SEC24C; DSCAML1;

MRVI1-AS1; UMODL1; C8orf47; IRX3; CASC2; AGTRAP; C2orf73; MLF1;

GRAMD1C; PPP1R42; DALRD3; NT5DC1; MCMDC2; P4HTM; ERBB4;

ZNF713; GPS; RIIAD1; Clorf173; TMEM107; CCDC89; C10orf67; ZNF664;

PLD6; FAM216B; Clorf194; TRNAU1AP; FGD6; TIGD2; GLIPR1L2;

KCNE1; WDFY3-AS2; ZFP3; OXTR; BBS12; NME9; RNF135; GPR135;

WRB; CYB5D1; CEP97; FAM104B; NGRN; SPATA13; CSMD1; FANCF;

RUVBL2; CCDC60; CDC125; C10orf107; TNFAIP8L3; DGCR6; C11orf88;

EFHC2; C9orf66; BTBD9; ANKRD45; DNAH2; HIST2H4A; LRTOMT;

EFNA5; C21orf128; PROS1; NELL2; FAM110C; PIGW; RBM43; ZFP90;

TMEM121; EFCAB10; LRRC37B; PGBD2; WBP5; PPIL6; KIAA0825; CDNF;

ARL15; TNFAIP8L1; RAD51D; SMYD3; MRPL40; MORNS; THNSL1;

RASA3; AGBL4; CYP2R1; C2orf76; SLC51B; KLHL32; PRELID2;

TMEM212; ANKRD37; AKAP14; ZNF396; FAM86B1; KATNA1; KIF24;

LYRM7; TMEM17; TMEM232; FAM183A; EFCAB6; TEAD1; SLIT1;

TSPYL4; DYNC2H1; WDR86; IFT140; C17orf97; C1orf170; DNAJB13;

AMY1C; MORN2; NWD1; TUBB4B; ENO4; FOCAD; TCTEX1D4; CERKL;

C9orf171; C12orf55; FAM154B; SNTN; PTPLAD2; Clorf192; FAM47E;

PTPRT; KIF19; TUBB; XPNPEP3; GRM7; ZNF569; C20orf96; ESRRG;

MY018A; TTC30B; ZNF33B; AMZ2; MVB12B; KIAA1211L; HIST3H2BB;

DTHD1; SRC; NEK5; SLC22A4; BCO2; KCNMB2; C5orf42; DNAH10;

WDR96; C4orf22; MEIG1; LEKR1; CCDC151; NUP62CL; MB; HMGN5;

ZNF607; ZNF627; KCNRG; CCDC69; CALM1; FAM179B; PPP1R14C;

FOXJ3; INPP5F; TSEN15; CIPC; DZIP3; L3MBTL3; DMD; ARMCX6; INF2;

FAM83H-AS1; EFCAB2; TATDN3; ECT2L; FAM229B; DDO; ATP1A1OS;

EFCAB7; LDLRAD1; LRRC73; SYS1; TRAF3IP1; NELFE; HSPA1L;

LY6G5C; GPANK1; Cl0orf115; TRIM39; CASC10; C9orf135; TTC25;

TCTN1; FAM201A; LRRC10B; TMEM231; C4orf47; TTLL10-AS1; OR7E36P;

DENND6B; ITPRIPL2; CRYZL1; PPAPDC2; C21orf49; HN1L; ANKUB1;

CCDC19; TCTEX1D2; ZNF625-ZNF20; TMEM110; CENPBD1P1; LIPE-AS1;

CLDN9; MYCBP; AMZ2P1; BBIP1; FAM187A; CPEB1; IFRD2; FAM166B;

C5orf49; SIAH3; TSTD1; FAM228B; C6orf226; AP4M1; TIAF1; DCDC2B;

ZNF844; DNAJC27-AS1; SLC25A5-AS1; LAMTOR5-AS1; PPP1R26-AS1;

BAIAP2-AS1; FAM66C; LINC01132; DNMBP-AS1; LINC00948; SRGAP3-AS2; UBAC2-AS1; VIM-AS1; TOB1-AS1; ANKRD66; STMND1; LINC00326;

LINC00271; TSPAN19; LYRM9; NKAPP1; PINLYP; SDCBP2-AS1; TEX21P;

LINC00094; C12orf75; TOPORS-AS1; SMKR1; LINC00886; HOGA1; SOX2-OT; ZNF709; ARHGEF26-AS1; ZNF487; WDR92; LINC00883; WDR65;

WDR86-AS1; TUBA4B; LIFR-AS1; USP2-AS1; BDNF-AS; CRNDE; H2AFJ;

ZBEDS-AS1; USP51; DYNLL1-AS1; SRP14-AS1; CCDC153; FMN1; UGDH-AS1; SPATS1; LINC01018; LRRC37BP1; GPR162; APITD1-CORT;

FAM86EP; STAU2-AS1; ATXN7L3B; RHPN1-AS1; ABCC6P2; DYX1C1;

C2lorf119; LINC01171; NHLRC4; OR7E47P; LINC00638; AQP4-AS1;

C15orf65; LINC00908; MAFG-AS1; ILF3-AS1; C19orf82; RNF157-AS1;

NAPA-AS1; HMGN3-AS1; FGF14-AS2; and CASC15.

15. The method of claim 14 , wherein the level of expression of each of COX6A1; COX7A2; RACGAP1; TPX2; NEK11; IFT88; RPL26; and RPL23 is determined.